Nuclear Medicine Innovation1

[WP-28-7] In vitro tumor cell-binding assay to select high-binding antibody and predict therapy response for personalized 64Cu-intraperitoneal radioimmunotherapy against peritoneal dissemination of pancreatic cancer.

Fukiko Hihara¹、Hiroki Matsumoto^1,4、Takashi Masuko²、Yuichi Endo Endo²、Chika Igarashi¹、Tomoko Tachibana¹、Gene Kurosawa³、Aya Sugyo¹、Atsushi B. Tsuji Tsuji¹、Yukie Yoshii¹ (1.National Institutes for Quantum Science and Technology、2. School of Pharmacy, Kindai University、3.International Center for Cell and Gene Therapy, Fujita Health University、4.Department of Diagnostic Radiology, Kanagawa Cancer Center)